Work

STELLA: A dose expansion of the ATR kinase inhibitor alnodesertib (ART0380) administered orally in combination with low-dose irinotecan to patients with advanced or metastatic CRC and PDAC.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps3184

Authors: Kim Anna Reiss, Babar Bashir, Susanna Varkey Ulahannan, Katrina Sophia Pedersen, Jason Timothy Henry, Meredith Pelster, Andrew Scott Paulson, Desiree Headley, Susana Barriga Falcon, Helen Millward, Amelia Fielding, Suraj Menon, Nicola Little, Alison Wilby, Graeme Smith, Ian C. Smith

Institutions: University of Pennsylvania, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, OU Health Stephenson Cancer Center, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), HealthONE, Sarah Cannon, Artios Pharma Limited (United Kingdom)

Language: English

Topic: DNA Repair Mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162688155

Cites:

Cited by:

Related to: